
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 10, 2026, 7:00 AM ET
Ocugen grants Celairis Therapeutics exclusive rights to commercialize OCU400 in Australia, New Zealand, and ASEAN markets, with payments up to $7.1 million.
Nasdaq: $OCGNBiotech · Gene therapyGoing-concern warning~32% of shares short
OCGN Stock Hub: Ocugen News, the December 22 Share Vote and the OCU400 Phase 3
Ocugen’s special meeting has one proposal left: raising the authorized share count by 250 million. It was adjourned in September and again in October and is now set for December 22, 2026, with a new record date of October 30. Until it passes, $130 million of convertible notes must be settled in cash, and the company’s June- and September-quarter reports state substantial doubt about its ability to continue as a going concern. On November 4 Ocugen reported $84.6 million of cash, restricted cash and short-term investments at September 30 and said it expects a runway into 2028. The stock trades below one dollar.
Full research report · PDF
Ocugen ($OCGN), research updated November 12, 2026
27 pages covering the November 10, 2026 Celairis license for OCU400 in Australia and ASEAN, the December 22 special meeting on authorized shares, the convertible notes, the September 30 balance sheet, the OCU400 and OCU410 programs, scenarios, sources and FAQ. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Next catalyst
December 22, 2026 · 8:00 a.m. Eastern · special meeting on the share increase
One proposal: raise authorized common stock from 390,000,000 to 640,000,000 shares. It needs a majority of all shares outstanding at the October 30 record date, and abstentions count as votes against. On September 21 only 160,214,431 shares, or 47.3%, were represented, against the 169,555,201 votes the proposal needed on the earlier record date. Form 8-K of October 15, 2026
Also: the coupon that fell due on November 15, as fixed by the indenture; as of November 17, 2026 the company had not reported whether it was paid. Third-quarter results were reported on November 4 (company release); the company expects final approval of OCU400 in The Bahamas and potential patient enrollment there as early as year-end.
OCGN stock at a glance
Chart analysis · JC
Technical chart analysis of $OCGN with bull and bear scenarios on JC Just Charts.
The vote · Dec 22
+250M
Authorized common from 390,000,000 to 640,000,000.
Convertible notes
$130M
6.75%, conversion price ~$2.68. Cash-settled until the increase takes effect.
Cash · Sep 30, 2026
$84.6M
Cash, equivalents, restricted cash and short-term investments; $100.4M of cash and restricted cash at June 30. The company expects a runway into 2028.
Going concern
Doubt
The September-quarter 10-Q, filed November 4, again states “substantial doubt” for the twelve months after the statements are issued.
Shareholders’ equity · Sep 30
−$17.7M
Assets $108.1M against liabilities of $125.7M; −$16.6M at June 30.
Short interest · Oct 30
31.7%
107,672,000 shares, 16.4 days to cover on Nasdaq figures; 102,053,118 at September 30.
Where Ocugen stands now
Ocugen has three gene therapies in registrational trials, no product revenue and no license application filed. The central question is the December 22 vote to raise authorized common from 390,000,000 to 640,000,000 shares. Cash, restricted cash and short-term investments were $84.6 million at September 30, down from $100.4 million of cash and restricted cash at June 30, and the company expects a runway into 2028; the third-quarter net loss was $3.6 million after a $16.6 million gain on the change in fair value of the derivative liability. Against that cash sit $130 million of 6.75% notes that can be settled only in cash until the increase is effective, and a going-concern warning. Three things decide what happens next: the vote, the Nasdaq bid-price count and the OCU400 topline guided to the first quarter of 2027. OCU400 has received Provisional Approval and Priority Designation from the Longevity and Regenerative Therapies (LARTA) Board of The Bahamas; the company expects final approval and potential patient enrollment as early as year-end. Q3 2026 business update · Form 10-Q for the September 2026 quarter · Form 10-Q for the June 2026 quarter
The main risk: the company has promised more shares than it is allowed to issue. At June 30, 2026 there were 339,044,893 shares outstanding and 122,396,448 potentially dilutive securities, about 461.4 million in total against 390,000,000 authorized, a calculation; at September 30 the counts were 339,306,603 and 122,596,196, about 461.9 million. The note indenture required approval by September 30, 2026, a date that has passed; Nasdaq rules cap conversion shares at 67,629,947 until shareholders approve; and under a letter agreement the chief executive may settle certain awards in cash if no amendment is approved by December 31, 2026.
▲ The constructive case
The balance sheet was rebuilt in six months: cash went from $18.6 million to $100.1 million, and the 12.25% secured loan was repaid along with its lien. At September 30 cash and investments were $84.6 million, with a runway the company expects to last into 2028. OCU400 Phase 3 is fully enrolled at 140 patients, with topline guided to the first quarter of 2027. OCU410 has been dosing a Phase 3 since September 1 after a Phase 2 that cut lesion growth 31% at the medium dose. By June two index managers held 8.0 and 6.3%.
▼ The cautious case
The going-concern warning and negative equity come from the company’s own report. The notes stay cash-settled until a vote adjourned twice without a decision. The stock has closed below the Nasdaq one-dollar minimum since October 8, after three earlier bid-price cycles. On the Stargardt trial the monitoring committee wrote that futility “could” be considered on the interim sample, and a securities class action was revived on appeal on September 30.
Latest Ocugen news
Nov 10, 2026
Ocugen and Celairis enter exclusive license agreement for OCU400 in Australia, New Zealand, ASEAN
Ocugen and Celairis Therapeutics executed an exclusive license agreement granting Celairis rights to commercialize OCU400 for retinitis pigmentosa in Australia, New Zealand, and ASEAN markets. Ocugen will receive an upfront license fee and potential development and milestone payments totaling up to $7.1 million, including $6.1 million associated with the upfront payment and OCU400 top-line results expected in the first quarter of 2027. Ocugen will also receive a high single-digit percentage royalty on net sales and 50% of gross profits from OCU400 net sales in the Territory. Celairis will be responsible for regional regulatory submissions, market access, and commercialization.
Nov 4, 2026
Ocugen Provides Business Update with Third Quarter 2026 Financial Results
Ocugen reported third quarter 2026 financial results and a business update. Cash, cash equivalents, restricted cash, and short-term investments totaled $84.6 million as of September 30, 2026, with runway expected into 2028. Total operating expenses were $19.7 million for the three months ended September 30, 2026, compared with $19.4 million a year earlier. Net loss per common share was $(0.01), compared with $(0.07) for the prior-year period.
Oct 29, 2026
Ocugen to participate in upcoming November investor and industry conferences
Ocugen, Inc. will present on its modifier gene therapy platform at investor and industry conferences in November 2026. It will present at the Stifel 2026 Healthcare Conference in New York, NY, on Thursday, November 12, 2026, and take part in a panel discussion at Cell & Gene Leaders Live 2026 in London, UK, on Sunday, November 15, 2026. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, is the presenter for both events. A webcast of the Stifel presentation will be available on the Company's website, with a replay available for 30 days.
Oct 22, 2026
Third-quarter results and business update on November 4
A conference call and webcast at 8:30 a.m. ET. The announcement contains no new clinical or regulatory data.
Oct 15, 2026
Investor presentation: Bahamas access programme and Phase 3 design
The slides restate OCU400 Phase 3 topline in the first quarter of 2027 and a BLA target in the second. For The Bahamas they expect full approval and patient dosing within 90 days under a regulated expanded access programme, with potential revenue of $1–2 million per patient. The OCU410 Phase 3 (about 237 patients) is shown with enrollment completion in 2027 and a BLA in 2028.
Oct 15, 2026
Roots supply agreement, and the special meeting postponed to December 22
A commercial supply agreement adds to the OCU400 licence for the Middle East and North Africa: Ocugen manufactures and supplies the product and owns the global safety database. The same filing reports that the board postponed the meeting, solely on the share-increase proposal, to December 22 with an October 30 record date.
OCGN stock catalysts: the dated calendar
- November 4, 2026 — Third-quarter results and business update: $84.6M of cash and investments at September 30, net loss $3.6M, runway expected into 2028. Completed
- November 6, 2026 — SEC proxy update: Ocugen filed definitive additional proxy materials for the reconvened December 22 virtual special meeting (8:00 a.m. ET). The only remaining vote is whether to increase authorized common shares by 250 million; shareholder approval has not yet occurred. The new record date is October 30, with 339,306,603 shares outstanding on that date. Phone/online proxies close at 11:59 p.m. ET on December 21; eligible holders may also vote during the December 22 meeting. Previously submitted proxies may remain valid subject to the company notice and any revocation. This filing does not itself authorize new shares or resolve the existing convertible-note cash-settlement risk. SEC Schedule DEFA14A, November 6. Filed
- November 10, 2026 — Exclusive OCU400 license to Celairis Therapeutics for Australia, New Zealand and ASEAN: payments of up to $7.1 million. Of that, up to $6.1 million combines an up-front license fee with a fee payable only if the Phase 3 liMeliGhT trial of OCU400 delivers positive topline results (expected in the first quarter of 2027); the Form 8-K does not split the two. The other $1.0 million is a milestone payable on approval by Australia’s Therapeutic Goods Administration. Ocugen also receives a high single-digit royalty on net sales and 50% of gross profits from OCU400 net sales in the territory. SEC Form 8-K, November 10, 2026. Signed
- November 15, 2026 — First cash coupon on the notes fell due; about $8.8 million a year, a calculation. Due by contract; as of November 17, 2026 the company had not reported whether it was paid
- November 18, 2026 — Thirtieth consecutive session below $1.00 if the streak continues, which would trigger a Nasdaq notice. Calculation, not an event yet
- December 22, 2026 — Special meeting on the +250,000,000 share increase. The event everything else depends on
- December 31, 2026 — Chief executive’s letter-agreement deadline for cash settlement of certain awards. Fixed by contract
- As early as year-end 2026 — OCU400 final approval in The Bahamas and potential first patient enrollment, after Provisional Approval and Priority Designation from the Longevity and Regenerative Therapies (LARTA) Board of The Bahamas. Company expectation
- First quarter of 2027 — OCU400 Phase 3 topline, 140 patients. Company guidance
- Second quarter of 2027 — First license application, for OCU400; OCU410ST topline. Company guidance
- May 15, 2027 — Earliest conversion date for the notes if the increase has not taken effect. Fixed by contract
- 2028 — OCU410 license application in geographic atrophy. Company guidance
The December 22 vote and the cash-settled notes
| Item | Detail |
|---|---|
| Record date | Close of business October 30, 2026 |
| Vote required | A majority of the voting power of all outstanding shares. On the July count that was 169,555,201 votes, a calculation |
| Abstentions | “Abstentions will have the same effect of a vote ‘AGAINST’ this proposal.” |
| Track record | On September 21, 160,214,431 shares were represented, 47.3% |
| Notes | $130.0 million, 6.75%, coupons May 15 and November 15; conversion price about $2.68; holders can put at par on May 15, 2032 |
| The clause that matters | No conversion before “the earlier of May 15, 2027 and the Reserved Share Effective Date,” and until then conversions are settled solely in cash |
Why the balance sheet looks worse than the cash. Because of that clause, at June 30 $116.1 million of notes and derivative sat in current liabilities, out of $140.8 million of total liabilities, which is why equity was negative on $124.2 million of assets. At September 30 the same two items totalled $100.3 million (a calculation) out of $118.9 million of current liabilities, and equity was −$17.7 million on $108.1 million of assets. A successful vote changes the accounting, not the cash.
The Ocugen pipeline
PHASE 3
OCU400 · retinitis pigmentosa
Gene-agnostic modifier therapy. The liMeliGhT Phase 3 is fully enrolled at 140 patients; topline guided to the first quarter of 2027 and a license application to the second. Licensed in the Middle East and North Africa to Roots Pharmaceutical and, since November 10, 2026, in Australia, New Zealand and ASEAN to Celairis Therapeutics, for up to $7.1 million in upfront, development and milestone payments plus royalties and a share of gross profits. OCU400 has Provisional Approval and Priority Designation from the Longevity and Regenerative Therapies (LARTA) Board of The Bahamas, where the company expects final approval and potential patient enrollment as early as year-end.
PHASE 3
OCU410 · geographic atrophy
Dosing a Phase 3 since September 1, 2026, on a single-pivotal design agreed with the FDA: ArMaDa3 plans 240 subjects randomized 2:1 to a single subretinal injection or untreated control, with lesion growth over 12 months as the primary endpoint. In the Phase 2, lesion growth was 31% lower at the medium dose (p<0.05) in the population matching pivotal criteria.
PHASE 2/3
OCU410ST · Stargardt disease
Fully dosed. On September 3, 2026 the monitoring committee noted that “one could consider futility” on the interim sample but recommended collecting the full eight-month dataset, which has not been reported. Topline from the 63-subject trial is anticipated in the second quarter of 2027, with a license application planned to follow.
Ocugen deep dive: the full analysis
The chapters below go through the company in detail: the scenarios, the December 22 vote and its arithmetic, the convertible notes and the cash-settlement clause, cash and the going-concern conclusion, the pipeline, the register and insider activity, the dated catalyst map, the red flags and the assessment. Every figure carries its date and its primary source. The same research is available as a downloadable PDF in the Research Library. The Merlintrader Research Library collects our dated biotech stock research reports.
01 OCGN stock scenarios: the vote, the notes and the 2027 readouts
These scenarios are ways of reading the situation, not forecasts, and none of them is a recommendation. Each one names the documents that would confirm or break it.
| Scenario | What it assumes | What would confirm it | What would break it |
|---|---|---|---|
| Bull | The vote passes on December 22 and the capital structure stops being the story. The share increase ends the cash-settlement requirement on the notes. That would move the $83.1 million of notes and the $17.1 million derivative that sat in current liabilities at September 30 back out of that classification, and those two items are what make equity negative (June 30 figures: $82.4 million and $33.7 million). Cash, restricted cash and short-term investments of $84.6 million at September 30, with a runway the company expects into 2028, are a real cushion. Three registrational programs are running, with OCU400 topline guided to 1Q 2027, a license application to 2Q 2027 and potential approval to 4Q 2027. | A Form 8-K reporting approval. A later report that reclassifies the notes as non-current. OCU400 topline on schedule. | A third failure to reach the threshold, another postponement, or an equity raise below a dollar before the notes are resolved. |
| Base | The vote passes, late or narrowly, and 2027 is spent funding three Phase 3 programs on a balance sheet that still carries $130 million of 6.75% debt. Nothing produces product revenue before a potential first approval in 4Q 2027. The open question is whether $84.6 million lasts through the OCU400 topline and a license application without new equity priced well below the last raises. | Cash near the September 30 level of $84.6 million with no new equity, shareholder approval in December, and a Stargardt dataset read without a stop. | Earlier approval than the guidance suggests, or a financing that resets the share count before the 2027 readouts. |
| Bear | The vote fails again and three contracts bind at once: • the notes stay cash-settled; • the Nasdaq cap holds conversion shares at 67,629,947; • from December 31 the chief executive can take certain awards in cash, plus interest and a tax gross-up. The stock is already below one dollar. If it stays there, a Nasdaq deficiency notice would follow, and a reverse split, the alternative the indenture always allowed, becomes the obvious route. | A failed vote or another postponement. A dilutive raise below $1.00. A futility stop in Stargardt. A bid-price notice under Rule 5550(a)(2). | Approval with the notes reclassified, or a partnership that funds the Phase 3 programs with someone else’s money. |
Ocugen is unusual because its next binary event is procedural, not scientific. The voters are fixed by the October 30 record date and the threshold is pure arithmetic. Brokers have discretion on this item, and in September 47.3% of the shares turned up. The company needs 50% plus one of everything outstanding, and an abstention counts the same as a vote against.
What would falsify this reading
The reading here is that the December 22 vote is the binding constraint and the convertible notes are the reason it binds. It treats the clinical programs as real but still far from revenue. The reading rests on the following points, and it would be damaged if any of them proved wrong.
The cash-settlement feature is in the filing, not inferred. The June-quarter report states that “unless and until the Reserved Share Effective Date occurs the Company is required to settle conversions solely in cash.” That clause is why an eight-year note sits in current liabilities, and why equity is negative.
The going-concern conclusion is the company’s own. The 10-Q concludes there is “substantial doubt about the Company’s ability to continue as a going concern within one year,” and the auditor said the same in the annual report. A reader who has only seen “cash runway into 2028” has seen one of two statements the company made about the same balance sheet.
The strongest argument the other way is that the capital question is already largely solved:
- Cash went from $18.6 million to $100.1 million.
- The secured loan was repaid.
- Burn in the June quarter was $12.2 million.
- The notes have no holder put before 2032.
On that view, the current-liability classification is an accounting effect of a clause that one vote removes, not a cash bill anyone expects to pay in 2026.
The clinical record is further from revenue than the designations suggest. No license application has been filed for any program. The Bahamian grant is an expanded-access authorization that depends on a further full approval. On the only pivotal trial with an interim already read, the monitoring committee recorded a negative direction of treatment effect.
02 OCGN stock: what the December 22 vote decides
Why the next event is procedural, not scientific
Most biotech stories turn on a regulator or a readout. This one does not. Ocugen has no application pending at the FDA, so there is no goal date and no advisory committee to wait for. What stands in front of the company is a corporate-law threshold: whether a majority of all outstanding shares will authorize 250 million more of them.
Where the meeting stands today. The special meeting convened on September 21, 2026 and was adjourned twice without a decision on the share proposal. On October 14 the board postponed it to Tuesday, December 22, 2026, at 8:00 a.m. Eastern, with a new record date of October 30. Only the share proposal remains, and the board recommends it unanimously. No tabulation of votes on it has been disclosed for either earlier session. Form 8-K (SEC) →
Why it matters: $130 million of convertible notes. They were issued in May 2026 at 6.75%, due 2034, convertible at about $2.68. Until the increase takes effect, conversions must be settled solely in cash, and Nasdaq caps share settlement at 67,629,947 shares. The indenture deadline for approval, September 30, has passed. A “best efforts” obligation now applies.
The company has promised more shares than it can issue. 339,044,893 shares were outstanding at June 30, plus 122,396,448 potentially dilutive securities. That is about 461.4 million against 390,000,000 authorized. A January 20, 2026 letter agreement lets the chief executive settle certain awards in cash if no amendment passes by December 31, 2026.
Two statements about one balance sheet. The August 6 results release guided to a runway into 2028, while the 10-Q filed the same day concluded there is substantial doubt about going concern. The cash chapter below sets the two statements side by side.
The one-line version. Against $84.6 million of cash and investments at September 30 sit $130 million of convertible principal. That money funds three gene therapies in registrational trials, none of them filed. Pass the vote and the notes stop being a current liability. Fail it and three obligations tighten at once, with a December 31 deadline on the third and the stock already below the Nasdaq minimum bid.
03 The vote, the arithmetic and the threshold
| Item | Detail |
|---|---|
| Meeting | Tuesday, December 22, 2026, 8:00 a.m. Eastern, virtual. It is the postponed session of a special meeting first convened on September 21 |
| Record date | Close of business October 30, 2026. The earlier sessions used July 27, when 339,110,401 shares were entitled to vote |
| Proposal | Amend the charter to raise authorized common stock from 390,000,000 to 640,000,000. Authorized preferred stays at 10,000,000, none issued |
| Vote required | A majority of the voting power of all outstanding shares. On the July count that was 169,555,201 votes, a calculation |
| Abstentions | Verbatim: “Abstentions will have the same effect of a vote ‘AGAINST’ this proposal.” |
| Broker discretion | Yes, so the company does not expect broker non-votes |
| Board recommendation | Unanimously FOR |
| Track record | On September 21, 160,214,431 shares were represented, 47.3%. The adjournment proposal passed 124,584,658 to 33,639,820 |
The arithmetic is the point. On September 21 the proposal would have failed by about 9.3 million votes even if every share present had voted yes. A new record date changes who can vote but not the standard. Because abstention counts as opposition, a shareholder who does nothing has the same effect as one who votes against. Registers heavy with retail holders often struggle with this standard.
Why the company says it wants the shares
The proxy gives three reasons:
- Flexibility. The general one is flexibility for “potential financings, business combinations, licensing arrangements or other corporate purposes,” with financings named first.
- The note indenture. Approval “would also ensure that we will have the option to settle conversion of the Notes in shares of common stock instead of cash.”
- The chief executive’s letter agreement, disclosed as his personal interest in the outcome. As described in the proxy, it allows certain of his January 2026 options, performance units and 2025 units to be settled in cash if no amendment is approved by December 31, 2026; an increase in authorized shares is the alternative the company presents.
The reverse split the indenture would also accept
No reverse split is on this ballot. The indenture accepts either route, because either one creates enough authorized, unissued shares. With the stock below one dollar, that alternative is now relevant twice: it would cover the note shares, and it is the usual cure for a bid-price deficiency. The only precedent is the 1-for-60 reverse split of September 2019, made immediately before the reverse merger that created the listed Ocugen.
Why a Delaware court was involved last time
The previous increase, to 390,000,000 shares in July 2024, drew a class action. It alleged the company “attempted to evade the voting threshold in the Company’s charter.” Ocugen petitioned the Court of Chancery under Section 205 of the Delaware General Corporation Law. On May 6, 2026 the court validated the amendment and every share issued under it, and the class action was dismissed as moot in July. Merlintrader reading: that history is likely why this proposal is being run as a standalone meeting with an explicit threshold.
04 The convertible notes and the cash-settlement clause
Everything unusual about this balance sheet comes from one instrument and one clause inside it.
| Term | Detail |
|---|---|
| Principal | $130.0 million: $115.0 million issued May 7, 2026 plus a $15.0 million over-allotment, placed under Rule 144A |
| Coupon and maturity | 6.75%, paid each May 15 and November 15, starting November 15, 2026. Stated maturity May 15, 2034; the same filing also references July 15, 2034 |
| Ranking | Senior unsecured, with no financial maintenance covenant disclosed |
| Conversion price | About $2.68 (372.7866 shares per $1,000), a contractual level far above the trading price, a calculation |
| The clause that matters | Not convertible before “the earlier of May 15, 2027 and the Reserved Share Effective Date,” and until that date conversions must be settled solely in cash |
| Nasdaq cap | 67,629,947 shares until shareholders approve; anything beyond is settled in cash. Up to 70,270,265 shares at the make-whole rate |
| Redemption and put | The issuer can redeem from May 15, 2029 if the stock trades at about $3.49. Holders can put at par on May 15, 2032, which is the practical maturity |
| Carrying value, June 30 | $82.4 million, current, plus a $33.7 million derivative liability. Fair value of the notes: $117.0 million. At September 30: $83.1 million and a $17.1 million derivative liability, both current (results release) |
Read the classification. A note with a 2032 put would normally be a non-current liability. This one sits in current liabilities, with the derivative beside it, and that classification is why shareholders’ equity is negative.
No holder can convert before May 2027 unless the increase takes effect first, and with conversion at about $2.68 and the shares trading far below it, no holder would want to. The balance sheet looks worse than the cash position because of a clause one vote removes. That vote is also what the company is obliged to pursue and has not yet obtained.
What the notes replaced
The proceeds, about $112.5 million net, retired a worse instrument. The Avenue Capital loan of November 2024 carried at least 12.25% and was secured on substantially all assets. It also gave the lenders a conversion right at 80% of the trading price, which had no floor. It was repaid on May 7, 2026 for about $32.7 million and the lien was released. Swapping a floorless 12.25% secured loan for a fixed 6.75% unsecured note is a clear improvement on its own terms. The price was the clause above. The only other debt is $1.5 million of a 4% EB-5 (immigrant investor program) facility.
Two things are absent. There is no at-the-market program and there are no pre-funded warrants. Equity can only be raised through announced transactions. The last three were at $1.00 in August 2025, at $1.50 in January 2026 and at $1.50 on a warrant exercise in March. All three are above the current trading level. The remaining 10,000,000 warrants at $1.50 expire in August 2027.
05 OCGN cash, burn and the going-concern conclusion
| Line | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Cash and equivalents | $100,051k | $18,571k |
| Restricted cash | $320k | $316k |
| Total assets | $124,206k | $43,516k |
| Convertible notes, current | $82,359k | — |
| Derivative liability, current | $33,708k | — |
| Total liabilities | $140,762k | $55,682k |
| Shareholders’ equity | Minus $16,556k | Minus $12,166k |
| Accumulated deficit | $452,121k | $408,067k |
Cash rose $81.5 million in six months, and none of it came from operations. Net cash used in operations was $21.8 million in the March quarter and $12.2 million in the June quarter, the second figure a calculation from cumulative data. The filings do not explain the fall in operating cash use between the two quarters, so neither quarter should be annualized. On the June rate the cash covers a little over eight quarters; on the first-half average, about six. Both figures are calculations. Both come before the full cost of three Phase 3 trials and before the $8.8 million annual coupon, also a calculation, which began on November 15.
Two statements, same day. On August 6, 2026 the results release said the notes were “extending cash runway into 2028.” The 10-Q filed that day concluded there is “substantial doubt about the Company’s ability to continue as a going concern within one year.” Its management discussion adds that the assessment includes “potential settlement and share reservation considerations associated with the convertible notes.” Both statements hold. On cash against burn, 2028 is defensible. On the accounting, a $116.1 million current obligation against $100.4 million of cash and restricted cash at June 30 produces the conclusion the filing reaches; at September 30 the same two items were $100.3 million (a calculation) against $84.6 million of cash and investments. No periodic report contains a quantified runway statement. The runway guidance has moved from “fourth quarter of 2026” in January to “into 2028” since May, and every version appeared in a press release.
Revenue. Ocugen has never had product revenue. The only line is non-cash collaborative revenue from the CanSinoBIO agreements, about $1.5 million a quarter in the first half of 2026 ($3.0 million in six months) and $1.95 million in the third quarter, and it was negative in the fourth quarter of 2025, a calculation. The June quarter carried $17.9 million of operating expenses and a net loss of $24.9 million. That loss included interest, the loss on retiring the Avenue loan and a move in the derivative.
The September quarter. On November 4, 2026, Ocugen reported third-quarter results. Cash, cash equivalents, restricted cash and short-term investments were $84.6 million at September 30, 2026, against $100.4 million of cash and restricted cash at June 30, and the company expects a runway into 2028. Operating expenses were $19.7 million (research and development $12.5 million, general and administrative $7.2 million) and revenue $1.95 million. The net loss was $3.6 million, or $0.01 per share, after a $16.6 million gain on the change in fair value of the derivative liability; the nine-month net loss was $47.7 million. At September 30 the convertible notes were carried at $83.1 million and the derivative liability at $17.1 million, both current, and shareholders’ equity was minus $17.7 million on total assets of $108.1 million; 339.3 million shares were outstanding. The Form 10-Q filed later on November 4 repeats the going-concern conclusion at September 30 and records nine-month operating cash use of $49.7 million. Form 10-Q for the quarter ended September 30, 2026 Q3 2026 results release (Form 8-K, Exhibit 99.1)
06 The Ocugen pipeline: three programs, no filing yet
The three gene therapies are all adeno-associated virus (AAV)-delivered modifier therapies licensed from a Harvard-affiliated eye institute, and all are in registrational trials. The useful way to read them is by how close each one is to a filing.
OCU400 — retinitis pigmentosa, the closest to a license application
OCU400 is gene-agnostic and addresses mutations across more than 100 genes.
- Trial design. The Phase 3 liMeliGhT trial (ClinicalTrials.gov NCT06388200; overall status active, not recruiting; enrollment 140 actual; last update posted July 31, 2026) is fully enrolled at 140 patients, randomized 2:1 against no treatment and open to children aged three and over. The primary endpoint is the 12-month change in a luminance-dependent navigation test.
- Timeline. Topline is guided to 1Q 2027, a license application to 2Q 2027 and potential approval to 4Q 2027. Manufacturing qualification batches are complete.
- Rolling submission. The FDA would need to see topline data at a pre-BLA (biologics license application) meeting before agreeing a rolling schedule.
- Clinical success. The October presentation defines it as at least a two-lux-level improvement at week 52.
The efficacy record so far is small: Phase 1/2 data in eight evaluable patients at three years, with seven of eight improved or kept against the untreated eye. No serious adverse events related to OCU400 have been reported.
The ex-US deals, read precisely.
- The Bahamas. On September 25 the Longevity and Regenerative Therapies (LARTA) Board of The Bahamas granted provisional approval and priority designation. It permits supply through an expanded access program, and only after a further full approval that has not yet been granted. The October 15, 2026 presentation expects full approval, site activation and first dosing within 90 days of that presentation, which is mid-January 2027 (a Merlintrader calculation); the November 4 business update says final approval and potential enrollment as early as year-end. The presentation cites potential revenue of $1–2 million per patient. This is not a marketing authorization, not an FDA or EMA action, and no revenue has been recognized.
- Middle East and North Africa. The definitive Roots Pharmaceutical license was signed on October 13 and announced on October 14: up to $4 million upfront and near-term, up to $255 million in sales milestones and a 22% royalty. A supply agreement signed October 13 has Ocugen manufacturing the product.
- South Korea. The Kwangdong license of September 2025 brought an initial $0.8 million fee.
OCU410ST — Stargardt disease, and the interim that used the word futility
The Phase 2/3 trial (ClinicalTrials.gov NCT05956626; overall status active, not recruiting; last update posted July 31, 2026) is fully dosed and randomized 2:1. ClinicalTrials.gov still listed an estimated primary completion of September 28, 2026 as of that July 31 registry update; that estimate is not a completed readout. The primary endpoint is the 12-month change in atrophic lesion size. Topline is guided to 2Q 2027, with a filing targeted for mid-2027.
On September 3, 2026 the independent monitoring committee completed an interim on 26 subjects at eight months, 16 treated and 10 control. It recommended collecting eight-month data on the whole population. Its reasoning, from the Form 8-K: it “noted that one could consider futility based on the negative direction of treatment effect on the interim sample and other interim results.” It still preferred the full dataset, because the small interim group carried a baseline lesion-size imbalance. That is not a futility stop. It is also not nothing. The full eight-month dataset has not been reported, and it is the most informative clinical fact likely before 2027. The supporting Phase 1 is encouraging but rests on six evaluable patients, with no p-values disclosed.
OCU410 — geographic atrophy, the strongest dataset and the newest trial
In the Phase 2, 51 patients were randomized to a medium dose, a high dose or no treatment. The headline result comes from the population that matches pivotal-trial lesion criteria: 31% less lesion growth at the medium dose, p<0.05, in a 28-patient comparison. The high dose showed 16%, and the full efficacy population 18% for both arms combined. The final figures came in below the preliminary January read. No treatment-related serious adverse events were reported. There were four choroidal neovascularization events, one of them in a control patient, which the committee judged unrelated.
A Type B meeting in July 2026 produced alignment with the FDA on a single pivotal trial pathway. The Phase 3 (ClinicalTrials.gov NCT07770828; overall status recruiting; enrollment 237 estimated; last update posted August 19, 2026) dosed its first patient on September 1, 2026: about 237 patients on the registry estimate, 240 on the company’s own plan, 2:1, at the medium dose, with enrollment completion shown for 2027 and a license application targeted for 2028. OCU410 received RMAT (regenerative medicine advanced therapy) designation on July 29, 2026.
The rest, briefly
- OCU200, a fusion protein for diabetic macular edema, is in Phase 1. Only safety has been disclosed.
- The inhaled vaccine platform has a Phase 1 funded entirely by a U.S. government institute, with no results yet.
- NeoCart, a cartilage cell therapy, waits on funding for a Phase 3.
In October the company also set up a European affiliate in Amsterdam, which adds cost and is not a regulatory event.
The regulatory position, stated plainly. Ocugen holds RMAT, orphan, rare-pediatric and advanced-therapy designations, and has agreed trial designs in the U.S. and Europe. It has never submitted a license application. No goal date or advisory committee exists, and no decision is pending at the FDA or the EMA. The first submission is guided to 2Q 2027.
07 Register, insiders, short position and the lawsuits
The register turned institutional by June 2026
There is no Schedule 13D on the company, so there is no activist and no strategic holder. The passive filings show a genuine rotation.
| Holder | Shares | % | Change | Event date |
|---|---|---|---|---|
| BlackRock | 26,952,492 | 8.0% | Up from 1.9% | June 30, 2026 |
| State Street | 21,469,307 | 6.3% | Up from 2.0% | June 30, 2026 |
| Millennium Management | 17,074,584 | 5.2% | New position | April 9, 2026 |
| Janus Henderson | 10,000,000 | 3.0% | Down from 20,000,000. The filing says the holding is “including 10,000,000 Warrants” | June 30, 2026 |
| The Vanguard Group | 0 | 0% | A reporting disaggregation, not a sale, as its own filing explains | March 13, 2026 |
No ownership position dated after June 30, 2026 has been filed: the most recent is the Schedule 13G filed on July 29 for holdings at June 30. All executive officers and directors together held 3.95% at the July 27 record date, and most of that was options.
Insiders: one purchase, two sales
The only open-market purchase by an insider in twelve months is 21,000 shares by the chief financial officer on June 15, 2026. The chief executive sold under a Rule 10b5-1 plan adopted June 5:
- 525,991 shares on September 9 and 525,991 shares on October 9, both under that plan.
After the October sale he held 4,018,470 shares directly and 1,030,771 through a holding company. His 2026 awards are large: 9,369,604 performance units, one-third tied to a market-capitalization milestone, plus an option over 3,123,201 shares at $1.38.
The potentially dilutive securities at June 30, 2026 were:
- Options: 29,952,963, weighted price $1.55.
- Restricted units: 2,346,235.
- Performance units: 11,838,639, up from 4,186,797 at the year end.
- Warrants: 10,628,664, of which 10,000,000 are at $1.50.
- Note shares: 67,629,947.
The total is 122,396,448, against 28,952,854 a year earlier. The equity plan’s evergreen adds 4% of the count every January, about 12.5 million shares this year. That is a standing claim on the authorized pool whatever the vote decides.
The short position
| Settlement date | Short interest | Days to cover |
|---|---|---|
| October 30, 2026 | 107,672,000 | 16.40 |
| September 30, 2026 | 102,053,118 | 13.66 |
| September 15, 2026 | 106,062,298, the peak before October 30 | 10.39 |
| August 31, 2026 | 98,309,421 | 28.24 |
| June 30, 2026 | 105,430,735 | 7.07 |
| December 31, 2025 | 46,392,427, the low of the series | 11.37 |
The September 15 level was about 31.3% of the shares outstanding, a calculation, and 32.1% of the float. The position grew about 129% in under nine months. It built through the January and March raises and the May note issue. Merlintrader reading: that pattern is consistent with convertible-arbitrage hedging alongside directional shorts; no capped call has been disclosed for the notes. At the October 30, 2026 settlement the figure was about 31.7% of the 339,306,603 shares outstanding (a calculation).
Four legal matters: one revived on appeal, two stayed, one resolved
| Matter | Status |
|---|---|
| Securities class action, E.D. Pennsylvania, 2:24-cv-01500 | Dismissed with prejudice in July 2025. On September 30, 2026 the Third Circuit vacated the dismissal and remanded in a precedential opinion on materiality. Back in the district court; no finding of liability (opinion) |
| Consolidated derivative actions, E.D. Pennsylvania | Stayed pending the appeal, which has now been decided. No change to the stay has been disclosed |
| Delaware derivative action, Chancery 2025-0095 | Fiduciary duty, unjust enrichment and insider trading claims. Stayed as last disclosed |
| Charter action and Section 205 petition | Resolved: the 2024 share increase was validated on May 6, 2026, and the class action was dismissed as moot |
No accrual has been recorded for any matter. The company states it believes the lawsuits are without merit.
Management and the Nasdaq question
The chief executive co-founded the company and has chaired it since 2013. In 2026 the turnover below him has been heavy:
- a new chief financial officer from February;
- the chief medical officer left on May 8;
- the chief accounting officer left on May 29, and the chief financial officer now holds both roles.
The listing is now a live question. The stock has closed below $1.00 at every session since October 8, 2026, twenty sessions to November 4, 2026. Under Rule 5550(a)(2), a deficiency notice follows 30 consecutive business days below a dollar. If every close from October 8 remains below $1.00, that thirtieth session would fall on November 18, 2026, a calculation. As of November 17, 2026, the company had not disclosed a Nasdaq deficiency notice under Rule 5550(a)(2).
Since 2019 Ocugen has been through three complete bid-price cycles, cured in January 2021, March 2024 and July 2025. Each needed a second 180-day period. Separately, equity is negative, and the company has not disclosed a Rule 5550(b) equity notice.
08 OCGN stock catalysts: the dated map
The catalyst map
| Window | Event | Status |
|---|---|---|
| November 4, 2026 | Third-quarter results and business update. The first September cash figure and the first full quarter of burn after the note issue. The notes were still classified as current at that date | Completed; date announced October 22, 2026 |
| November 15, 2026 | First cash coupon on the notes; the annual coupon is about $8.8 million (a calculation) | Fixed by contract |
| November 18, 2026 | The thirtieth consecutive session below $1.00 if the October 8–November 4 streak continues with no close at or above $1.00, triggering a Nasdaq notice | Calculation, not an event yet |
| December 22, 2026, 8:00 a.m. ET | The special meeting. One proposal: +250,000,000 authorized shares, majority of all shares outstanding at October 30 | Fixed by filing. The event everything else depends on |
| Days after the vote | A Form 8-K with the result under Item 5.07. If the proposal passes, a certificate of amendment filed in Delaware, which is what makes the increase effective | Required by rule |
| December 31, 2026 | The chief executive’s letter-agreement deadline: without an amendment, cash settlement of certain awards with interest and a tax gross-up | Fixed by contract |
| As early as year-end 2026 | LARTA final approval of OCU400 in The Bahamas and potential first patient enrollment, after Provisional Approval and Priority Designation (company expectation). Undated: the full eight-month Stargardt dataset; the remanded class action’s schedule | No dates disclosed |
| First quarter of 2027 | OCU400 Phase 3 topline, 140 patients | Company guidance |
| Second quarter of 2027 | First license application, for OCU400; OCU410ST topline | Company guidance |
| May 15, 2027 | Earliest conversion date for the notes if the increase has not taken effect | Fixed by contract |
| Fourth quarter of 2027 | Potential OCU400 approval | Company guidance; nothing filed |
| 2028 | OCU410 license application in geographic atrophy | Company guidance |
09 OCGN red flags, what to watch and the bottom line
The full list of red flags, with the dated figures behind each one, is in the Red flags section after the Health Score.
What to watch, in order
- The 8-K after December 22, and whether it reports a result or another postponement. If the proposal passes, watch for the certificate of amendment in Delaware.
- The 2026 Form 10-K: the auditor’s going-concern wording and the classification of the notes at December 31.
- The bid price against the one-dollar Nasdaq minimum, and any notice under Rule 5550(a)(2).
- Any equity issuance and its price. With no at-the-market facility, it would have to be announced.
- The full eight-month Stargardt dataset.
- The Bahamian full approval, and whether any revenue is ever recognized from it.
- OCU400 topline in the first quarter of 2027, the first event about the medicine rather than the capital structure.
Merlintrader bottom line
Ocugen is the rare biotech whose next binary event is written in corporate law, not in a protocol. Nothing is filed at any regulator. What there is instead is a meeting on December 22, 2026, one proposal, and a threshold equal to a majority of the shares outstanding at the October 30 record date.
The case for taking the vote lightly is real:
- $84.6 million of cash and investments at September 30 and a runway the company expects into 2028;
- the secured loan repaid;
- notes nobody would convert at about $2.68 while the shares trade below a dollar;
- three programs in registrational trials, including a Phase 2 result of 31% at p<0.05 in geographic atrophy;
- a register that turned institutional by June.
On that reading, the current-liability classification is an accounting effect of a clause that one vote removes.
The case for taking it seriously is that the company itself does:
- a going-concern conclusion and negative equity;
- an indenture date already passed;
- two sessions without a decision;
- a December 31 cash deadline tied to the chief executive’s awards;
- since October, a share price under the Nasdaq minimum.
If the vote fails again, the reverse split the indenture always allowed becomes the obvious way to solve both the share shortage and the listing problem, at a price.
Neither case is about the medicine, and that is the real weakness here. The clinical evidence is promising and thin at the same time. A Bahamian provisional approval and a definitive regional license do not change the core fact that nothing has been filed in the U.S. or Europe. So the test needs no view on gene therapy. Watch whether the vote passes on December 22, whether the 2026 Form 10-K keeps the going-concern wording and cash holds without new equity, and whether the stock closes back above one dollar before a Nasdaq notice.
None of this is a recommendation, a target or a view on the share price.
Not yet disclosed or announced as of November 17, 2026:
- the outcome of the December 22 meeting;
- any vote tabulation on the proposal at the September 21 or October 5 sessions;
- any quantified runway in a periodic report;
- any license application or pending regulatory decision;
- a date for the Bahamian full approval, or any revenue from it or from the Middle East license;
- the full eight-month Stargardt result;
- any schedule in the remanded securities case;
- any Nasdaq deficiency notice;
- any ownership filing dated after June 30, 2026, beyond the Schedule 13G filed on July 29 for positions at June 30;
- any analyst rating or target;
- the payment of the coupon that fell due on November 15, 2026.
Two inconsistencies remain in the company’s own disclosures. The note maturity appears as both May 15 and July 15, 2034. The Stargardt trial size appears as 63 dosed in April but as a 51-patient design in later slides.
Merlintrader Health Score · $OCGN
2.10out of 5
Assessed on November 5, 2026, on the Form 10-Q for the quarter ended September 30, 2026; previously 1.9 on October 26, 2026. Reviewed November 10, 2026, after the Celairis license, with the scores unchanged. Weighted calculation: 1.5×30% + 3.0×30% + 1.5×20% + 2.5×10% + 2.0×10% = 2.10. The score describes financial and operational robustness over twelve to eighteen months. It is not a rating, a target price or an indication to buy or sell.
Red flags
- Going-concern conclusion in the company’s own 10-Q and in the auditor’s report.
- Equity was minus $16.6 million at June 30 and minus $17.7 million at September 30. $116.1 million of notes and derivative was classified as current at June 30, against $100.4 million of cash and restricted cash; at September 30, $100.3 million against $84.6 million of cash and investments.
- The September 30 indenture deadline passed without approval; the vote has been adjourned twice without a decision.
- Abstentions count against, and brokers already have discretion: no mechanical route closes a turnout gap.
- About 461.9 million shares were committed at September 30 against 390 million authorized.
- A December 31 deadline turns a failed vote into a cash cost through the chief executive’s awards.
- Below one dollar at every close since October 8, with three earlier bid-price cycles.
- No at-the-market facility.
- The Stargardt monitoring committee raised futility on the interim sample, and the full dataset is still unread.
- No license application has ever been filed, and the closest program’s efficacy rests on eight evaluable patients.
- Short interest of about 31.7% of the shares at the October 30, 2026 settlement.
- A revived securities class action and two stayed derivative suits, with no accrual recorded.
- Two senior departures in May 2026, with the financial and accounting officer roles now held by one person.
- The chief executive sold 1,051,982 shares in two blocks; the only insider purchase was 21,000 shares.
OCGN Stock FAQ: Ocugen Questions Answered
When is Ocugen’s vote to increase authorized shares?
Ocugen’s special shareholder meeting is scheduled for December 22, 2026 at 8 a.m. ET, with an October 30 record date. Shareholders will vote on increasing authorized common shares by 250 million, from 390 million to 640 million, after two adjournments. Meeting postponement filing.
Is Ocugen’s OCU400 FDA approved?
As of November 17, 2026, OCU400 was not FDA approved and Ocugen had not filed a license application, leaving no FDA action date or advisory committee scheduled. Outside the U.S., OCU400 has Provisional Approval and Priority Designation from the Longevity and Regenerative Therapies (LARTA) Board of The Bahamas, with final approval expected as early as year-end, according to the company. Management guides Phase 3 topline to Q1 2027 and an OCU400 application to Q2 2027. Pipeline and regulatory timetable.
How much cash does Ocugen have, and how long will it last?
Ocugen held $84.6 million of cash, cash equivalents, restricted cash and short-term investments at September 30, 2026, against $100.4 million of cash and restricted cash at June 30, and expects that to extend its runway into 2028. Its September-quarter Form 10-Q, filed November 4, again states substantial doubt about its ability to continue as a going concern within one year after the financial statements are issued. Q3 Form 10-Q. Q3 2026 cash and runway. The cash-settlement terms of the notes and the cost of the ongoing trials are the main calls on that cash. Cash flow and liquidity. First-quarter cash flow.
Is OCGN stock at risk of dilution?
Yes: Ocugen is seeking 250 million more authorized shares at its December 22, 2026 meeting, supporting potential conversion of $130 million in 6.75% notes. Until approval, the notes remain cash-settled and in current liabilities, with conversion shares capped at 67,629,947. If approval is absent by December 31, the chief executive may cash-settle certain vested or exercised awards; the indenture’s best-efforts obligation continues and allows a reverse split as an alternative. Notes and share obligations. Share-vote schedule. Proxy and award-settlement terms.
When does Ocugen report earnings?
Ocugen reported Q3 2026 results and a business update on November 4, 2026, with a conference call: cash and investments of $84.6 million at September 30, a net loss of $0.01 per share and an expected runway into 2028. The date of the next results has not yet been announced. Q3 2026 business update.
What does Ocugen do?
Ocugen develops gene therapies for inherited and age-related retinal diseases. Its lead modifier gene therapy, OCU400, is in Phase 3 for retinitis pigmentosa; OCU410 targets geographic atrophy and OCU410ST targets Stargardt disease. The company has no FDA-approved commercial product. Company pipeline.
When will Ocugen report OCU400 Phase 3 results?
Ocugen’s October 2026 presentation guides OCU400 Phase 3 topline to Q1 2027, following full enrollment of 140 patients in liMeliGhT, and the November 4 update repeated the first-quarter 2027 timing, followed by a planned BLA submission. A first license application is planned for Q2 2027. The program is intended to treat retinitis pigmentosa across multiple genetic causes. OCU400 development plan.
Primary sources
- Company release, November 10, 2026: exclusive OCU400 license to Celairis Therapeutics for Australia, New Zealand and ASEAN
- Company release, November 4, 2026: business update with third-quarter 2026 results
- Form 10-Q, quarter ended September 30, 2026, filed November 4, 2026
- Form 8-K, November 4, 2026: third-quarter results (Item 2.02)
- Form 8-K, October 15, 2026: Roots supply agreement and meeting postponement
- October 2026 investor presentation (Exhibit 99.1)
- Form 10-Q, quarter ended June 30, 2026
- Form 4, October 13, 2026: chief executive’s sale of October 9
- Company release, October 22, 2026: date of the third-quarter results and business update
- Company release, October 14, 2026: Roots Pharmaceutical license for OCU400 in the Middle East and North Africa
- Third Circuit opinion, No. 25-2653
- Nasdaq short-interest table
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $OCGN or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, official trial registries, regulatory agency documents and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, shareholder votes fail, exchange listing standards are enforced, and development-stage companies frequently raise equity at whatever price the market will bear. This company reports substantial doubt about its ability to continue as a going concern, carries negative shareholders’ equity and has no product revenue and no license application on file with any regulator. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



